There is increasing recognition and acceptance from physicians and researchers that there may be vast therapeutic potential for cannabinoids, including THC and also cannabidiol (“CBD”), which is not mind-altering. This interest has led independent research investigators to conduct a wide variety of preclinical and clinical studies to examine their therapeutic benefits, including for treatment of the disease indications listed below.

Independent Clinical Trials

  • Inflammatory Bowel Disease
  • Opiate Dependence
  • Epilepsy
  • Muscle spasticity (in Multiple Sclerosis)
  • Neuropathic Pain
  • Huntington’s Disease

Serious Unmet Needs in IBD and Digestive Disorders

  • Cannabinoids have been demonstrated to help Crohn’s disease patients enter into remission, and clinical studies have found that 84% of inflammatory bowel disease patients using cannabis report improvement in abdominal pain (Storr et al., Inflammatory Bowel Diseases, 2014). There are 1.4 million Americans with IBD, and over half of nonusers have reported an interest in use of cannabis for symptomatic relief.
  • A large number of studies have confirmed the role of the endocannabinoid system in the control of gut motility, secretion, and mucosal or barrier integrity, as well as its role in determining the course of intestinal inflammation and cancer. The endocannabinoid system therefore provides many drug targets for digestive or gastrointestinal disorders, such as inflammatory bowel disease, narcotic bowel syndrome (a severe form of opiate-induced abdominal pain), irritable bowel syndrome, colon cancer, and more.